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Alpha1-antitrypsin deficiency results from point mutations that distort the structure of the protein to allow a unique
protein–protein interaction that we have termed loop-sheet polymerization. Polymers of Z a1-antitrypsin
accumulate within hepatocytes to form inclusion bodies that are associated with juvenile cirrhosis and
hepatocellular carcinoma. The lack of circulating protein predisposes the Z a1-antitrypsin homozygote to
emphysema. This polymerization process also occurs in variants of other members of the serine proteinase inhibitor
(serpin) superfamily, antithrombin, C1-inhibitor and a1-antichymotrypsin in association with thrombosis, angio-
oedema and chronic obstructive pulmonary disease respectively, and we have recently shown that it underlies a
novel inclusion body dementia. Understanding this mechanism of polymerization allows rational drug design to
block the protein–protein linkage and so ameliorate the associated disease.
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deficiency
Alpha1-antitrypsin deficiency was first described as a
clinical entity in 1963 by Laurell and Eriksson who noted
an absence of the a1 band on serum protein electrophoresis.
The major function of a1-antitrypsin is to protect the tissues
against the enzyme neutrophil elastase (1). Its role in
protecting the lungs against proteolytic attack is under-
scored by the association of plasma deficiency with early
onset panlobular emphysema, asthma, bronchiectasis and
Wegener’s granulomatosis. Over 70 naturally occurring
variants have been described and characterized by their
migration on isoelectric focusing gels. The two most
common deficiency variants, S and Z, result from point
mutations in the a1-antitrypsin gene and make the protein
migrate more slowly than normal M a1-antitrypsin on
isoelectric focusing. S a1-antitrypsin (
264Glu)Val) is found
in up to 28% of Southern Europeans and although it results
in plasma a1-antitrypsin levels that are 60% of the M allele
it is not associated with any pulmonary sequelae. The Z
variant (342Glu)Lys) results in a more severe deficiency
which is characterized in the homozygote by plasma a1-
antitrypsin levels of 10% of the normal M allele and byCorrespondence should be addressed to: David A. Lomas,
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allele and 10% from the Z allele). The Z mutation results in
the accumulation of a1-antitrypsin as inclusions in the
rough endoplasmic reticulum of the liver. These inclusions
predispose the homozygote to juvenile hepatitis, cirrhosis
and hepatocellular carcinoma (2).
Alpha1-antitrypsin deficiency and
polymerization
Alpha1-antitrypsin is the archetypal member of the serine
proteinase inhibitor or serpin superfamily. This family
includes proteins such as a1-antichymotrypsin, C1 esterase
inhibitor, antithrombin and plasminogen activator inhibi-
tor-1 which play important roles in the control of
proteinases involved in the inflammatory, complement,
coagulation and fibrinolytic cascades (3). Members of the
family have a similar structure characterized by three b-
sheets (A–C) and nine a-helices. This scaold supports an
exposed mobile reactive loop that presents a peptide
sequence as a pseudosubstrate for the target proteinase.
After docking the proteinase is inactivated by a mousetrap
action that swings it from the top to the bottom of the
protein in association with the insertion of an extra strand
in b-sheet A (4). This six-stranded protein bound to its
target enzyme is then recognized by hepatic receptors and
cleared from the circulation.
The structure of the serpins is very much a dual edged
sword in that it is central to their role as eective anti-
proteinases but also renders them liable to undergo# 2000 HARCOURT PUBLISHERS LTD
FIG. l. The molecular basis of loop-sheet polymerization. (a) The reactive loop of a1-antitrypsin (red) is held as a b-strand
that can readily insert into b-sheet A of a second molecule (green). The linkage is facilitated by mutations that perturb b-
sheet A thereby making it more receptive to the peptide loop of another molecule of a1-antitrypsin. (b) A dimer of a1-anti-
trypsin showing the reactive centre loop of one molecule inserting into b-sheet A of a second. (c) This process can extend to
form chains of polymers. In the model each a1-antitrypsin molecule is shown in a dierent colour.
S4 D. A. LOMASconformational change in association with disease. Point
mutations can destabilize b-sheet A to allow incorporation
of the loop of another serpin molecule. Sequential loop
insertion results in chains of polymers that are retained
within the cell of synthesis. This process is best character-
ized for the severe Z deficiency variant of a1-antitrypsin that
results in protein retention in hepatocytes in association
with cirrhosis (5). The Z mutation of a1-antitrypsin is atresidue P17 (17 residues proximal to the P1 reactive centre)
at the head of strand 5 of b-sheet A and the base of the
mobile reactive loop [Fig. 1(a)]. The mutation opens b-sheet
A, thereby favouring the insertion of the reactive loop of a
second a1-antitrypsin molecule to form a dimer [Fig. 1(b)].
This can then extend to form polymers [Fig. 1(c)] that
tangle in the endoplasmic reticulum of the liver to form
inclusion bodies (6). Support for this comes from the
LOOP-SHEET POLYMERIZATION S5demonstration that Z a1-antitrypsin formed chains of
polymers when incubated under physiological conditions.
The rate was accelerated by raising the temperature to 418C
and could be blocked by peptides that compete with the
loop for annealing to b-sheet A (5). The role of
polymerization in vivo was clarified by the finding of a1-
antitrypsin polymers in inclusion bodies from the livers of
Z a1-antitrypsin homozygotes.
Although many a1-antitrypsin deficiency variants have
been described, only two other mutants of a1-antitrypsin
have similarly been associated with plasma deficiency and
hepatic inclusions: a1-antitrypsin Siiyama (
53Ser)Phe) and
a1-antitrypsin Mmalton (
52Phe deleted). Both of these
mutants also destabilize b-sheet A to allow the formation
of loop-sheet polymers in vivo (7). The temperature and
concentration dependence of polymerization, along with
genetic factors (8), may account for the heterogeneity in
liver disease amongst individuals who are homozygous for
the Z mutation. As a1-antitrypsin is an acute phase protein
the concentration will rise during episodes of inflammation.
At these times the formation of polymers is likely to
overwhelm the degradative pathway thereby exacerbating
the formation of hepatic inclusions and the associated
hepatocellular damage.
Recent investigations have shown that polymerization
also underlies the mild plasma deficiency of the S and I
variants of a1-antitrypsin (9). The point mutations that are
responsible for these variants have less eect on b-sheet A
than does the Z variant. Thus the rates of polymer
formation are much slower than that of Z a1-antitrypsin
which results in less retention of protein within hepatocytes,
milder plasma deficiency and the lack of a clinical
phenotype. However if a mild, slowly polymerizing I or S
variant of a1-antitrypsin is inherited with a rapidly
polymerizing Z variant then the two can interact to form
heteropolymers within hepatocytes, inclusions and cirrhosis
(9).
Polymerization of serpins underlies
chronic obstructive pulmonary
disease, thrombosis, angio-oedema
and dementia
The single most important factor in the development of
emphysema in patients with a1-antitrypsin deficiency is
smoking (10). The combination of anti-proteinase defi-
ciency and cigarette smoke can have a devastating eect on
lung function. We have shown that the anti-proteinase
screen within the lung can be further reduced in Z a1-anti-
trypsin homozygotes by the spontaneous formation of
loop-sheet polymers (11). This conformational transition
inactivates the protein, thereby further reducing the already
depleted levels of a1-antitrypsin that are available to protect
the lungs. The relationship of intra-pulmonary Z
a1-antitrypsin polymers to smoking, infection and rate of
decline in lung function in Z homozygotes requires further
evaluation in prospective studies.The phenomenon of loop-sheet polymerization is not
restricted to a1-antitrypsin and has now been reported in
other serpin variants to cause disease. Mutants of C1-
inhibitor, antithrombin and a1-antichymotrypsin can also
destabilize the serpin architecture to form inactive polymers
that are associated with angio-oedema, thrombosis and
chronic obstructive pulmonary disease respectively (12).
The process is most striking in a recently described
inclusion body dementia, familial encephalopathy with
neuroserpin inclusion bodies (FENIB), that results from
polymerization of the neurone-specific serpin, neuroserpin
(13). The dementia has been described in two Caucasian
families in the United States. In the first family, 95% of
aected individuals presented with dementia between the
ages of 45 and 56. The second family had an earlier age of
onset of symptoms with epilepsy and progressive decline in
cognitive function occurring in the second and third
decades of life. Both were characterized by eosinophilic
neuronal inclusion bodies in the deeper layers of the
cerebral cortex and the substantia nigra. The inclusions
were PAS-positive and diastase-resistant and had a striking
resemblance to those of Z a1-antitrypsin in the hepatocytes
of homozygotes with cirrhosis. Biochemical analysis
revealed that the inclusions were formed of neuroserpin
and that aected individuals carried point mutations in
a region that was critical to protein function. Structural
analysis showed that the mutant neuroserpin had formed
intraneuronal polymers that were identical to those of
Z a1-antitrypsin (13). Thus therapies that attenuate
serpin polymerization may be useful in a whole range of
diseases.
Treatment of patients with
a1-antitrypsin deficiency
This new understanding of the structural basis of a1-anti-
trypsin deficiency provides a platform for rational drug
design to block polymerization in vivo and so attenuate the
associated liver disease (14). Any therapy that improves
secretion from the liver will raise the circulating levels of a1-
antitrypsin and so enhance the anti-proteinase protection
within the lung. Until that time the prevention of
emphysema is better than cure and there is good evidence
that many Z a1-antitrypsin homozygotes would develop
only mild lung disease if they abstain from smoking (10).
The genetic deficiency in the anti-elastase screen may be
rectified biochemically by intravenous infusions of a1-anti-
trypsin. There is registry data to suggest that this therapy
may slow the rate of decline in lung function in patients
with an FEV1 of 35–49% predicted but this has yet to be
proven in randomized, controlled trails (15).
In the meantime, patients with a1-antitrypsin deficiency
related emphysema should receive conventional therapy
with advice on smoking cessation, trials of bronchodilators
and inhaled corticosteroids and, where appropriate, assess-
ment for long-term oxygen therapy and single lung
transplantation. The role of lung volume reduction surgery
in this group is unclear.
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